✦ LIBER ✦

PUK15 COST IMPLICATIONS OF INTRAVENOUS (IV) BEVACIZUMAB TREATMENT IN PATIENTS WITH RENAL CELL CARCINOMA (RCC)

✍ Scribed by AA Fournier; MS Duh; É Moyneur; E Dial; MP Neary; WK Oh

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PUK1 INCIDENCE AND COST OF ADVERSE EVENT

✍ E Dial; MS Duh; L Antras; D Rodermund; MP Neary; TK Choueiri; WK Oh 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

PUK17 Cost-Mimimization Analysis of Pazo

✍ M. Sura; S. Goryaynov; M. Avxentyeva; V. Omelyanovsky 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

PCN56 COST OF RENAL CELL CARCINOMA TREAT

✍ T Purmonen; R Vuorinen; V Kataja; S Pyrhönen; P Kellokumpu-Lehtinen 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

PCN53 RETROSPECTIVE US CLAIMS DATABASE A

✍ E Moyneur; T Dorff; V Barghout; S Meyers; J Hu; D Quinn 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

7133 POSTER Treatment (tx) Patterns and

✍ Castellano, D.; Duh, M.S.; Suthoff, E. Dial; Korves, C.; Vekeman, F.; Ramamurthy 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 58 KB

PCN111 INFLUENCE OF AGE ON COMORBIDITIES

✍ TB Dorff; E Moyneur; V Barghout; DI Quinn 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB